Process evaluation of a data-driven quality improvement program within a cluster randomised controlled trial to improve coronary heart disease management in Australian primary care

PLoS One. 2024 Jun 4;19(6):e0298777. doi: 10.1371/journal.pone.0298777. eCollection 2024.

Abstract

Background: This study evaluates primary care practices' engagement with various features of a quality improvement (QI) intervention for patients with coronary heart disease (CHD) in four Australian states.

Methods: Twenty-seven practices participated in the QI intervention from November 2019 -November 2020. A combination of surveys, semi-structured interviews and other materials within the QUality improvement in primary care to prevent hospitalisations and improve Effectiveness and efficiency of care for people Living with heart disease (QUEL) study were used in the process evaluation. Data were summarised using descriptive statistical and thematic analyses for 26 practices.

Results: Sixty-four practice team members and Primary Health Networks staff provided feedback, and nine of the 63 participants participated in the interviews. Seventy-eight percent (40/54) were either general practitioners or practice managers. Although 69% of the practices self-reported improvement in their management of heart disease, engagement with the intervention varied. Forty-two percent (11/26) of the practices attended five or more learning workshops, 69% (18/26) used Plan-Do-Study-Act cycles, and the median (Interquartile intervals) visits per practice to the online SharePoint site were 170 (146-252) visits. Qualitative data identified learning workshops and monthly feedback reports as the key features of the intervention.

Conclusion: Practice engagement in a multi-featured data-driven QI intervention was common, with learning workshops and monthly feedback reports identified as the most useful features. A better understanding of these features will help influence future implementation of similar interventions.

Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12619001790134.

MeSH terms

  • Australia
  • Coronary Disease* / therapy
  • Disease Management
  • Female
  • Humans
  • Male
  • Primary Health Care*
  • Quality Improvement*

Grants and funding

Funding for this study was provided by a National Health and Medical Research Council (NHMRC) Partnership Project Grant (Award Grant Number: GNT1140807). Additional in-kind and cash support from the following partner organisations; Amgen (cash support), Austin Health, Australian Cardiovascular Health and Rehabilitation Association, Australian Commission on Safety and Quality in Health Care, Australian Primary Health Care Nurses Association, Brisbane South PHN, Fairfield General Practice Unit, Heart Support Australia, Improvement Foundation, Inala Primary Care, National Heart Foundation of Australia, Nepean Blue Mountains PHN (cash support), Royal Australian College of General Practitioners, Sanofi (provided cash support via the Externally Sponsored Collaboration pathway), South Western Sydney PHN, The George Institute for Global Health (cash support) and University of Melbourne. The funders, including funding body and industry partners had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.